Compare KN & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KN | CELC |
|---|---|---|
| Founded | 1946 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Consumer Electronics/Appliances | Medical Specialities |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 3.1B |
| IPO Year | 2013 | 2017 |
| Metric | KN | CELC |
|---|---|---|
| Price | $36.89 | $123.46 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 9 |
| Target Price | $28.00 | ★ $112.56 |
| AVG Volume (30 Days) | 936.4K | ★ 961.0K |
| Earning Date | 04-23-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 118.94 | N/A |
| EPS | ★ 0.11 | N/A |
| Revenue | ★ $593,200,000.00 | N/A |
| Revenue This Year | $9.40 | N/A |
| Revenue Next Year | $6.98 | $720.19 |
| P/E Ratio | $335.82 | ★ N/A |
| Revenue Growth | ★ 7.17 | N/A |
| 52 Week Low | $16.09 | $10.26 |
| 52 Week High | $37.08 | $151.02 |
| Indicator | KN | CELC |
|---|---|---|
| Relative Strength Index (RSI) | 76.25 | 49.39 |
| Support Level | $23.56 | $100.58 |
| Resistance Level | N/A | $151.02 |
| Average True Range (ATR) | 1.29 | 8.22 |
| MACD | 0.39 | -0.89 |
| Stochastic Oscillator | 98.35 | 38.88 |
Knowles Corp is engaged in the manufacturing of micro-acoustic microphones and balanced armature speakers, audio solutions, high-performance capacitors, and radio frequency filtering products. It operates in two segments; the Precision Devices segment specializes in the design and delivery of high-performance capacitor products and RF solutions; and Medtech & Specialty Audio segment designs and manufactures microphones and balanced armature speakers used in applications. The majority of its revenue comes from the Precision Devices. Geographically, it operates in United States, Asia, Other Americas, Europe and Others, out of which United States generates maximum revenue.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.